ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays Kaposi Study, Blocks Monitoring Plan

February 26, 1982

In Brief: Carter Transition Team Lists Prospects For HEW Secretary; Interferon Available

December 3, 1976

In Brief: Steve Carter Accepts Job With Bristol, Phillips Elected NCG Chairman; Murray Copeland Dies

April 9, 1982

Phase III Trial Would Give Clearer Picture of C225 Role

March 8, 2002

Clinical Trials: Stories On Results Can Have Unintended Consequences

May 15, 1998

House Committee Aims To Cut Markup On Office-Administered Cancer Drugs.

November 16, 2001